Zepbound Clinical Trial Findings - Search News

Order byBest matchMost fresh

News

Zepbound beats Wegovy for weight loss

Zepbound beats Wegovy for weight loss in first head-to-head trial of blockbuster drugs

People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in the first head-to-head study of the blockbuster medications. Clinical trial participants who took tirzepatide,

Continue reading

· 3d · on MSN

Becker's Hospital Review · 2d

Zepbound beats Wegovy for weight loss: Study

EconoTimes · 2d

Eli Lilly’s Zepbound Outperforms Wegovy in Weight Loss Head-to-Head Trial

3d

Why Patients Are Being Forced to Switch to a 2nd-Choice Obesity Drug

CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed ...

Dual-target weight-loss drug is 47% more effective than its rival

The first clinical trial comparing semaglutide and tirzepatide, two popular, injectable weight-loss drugs, has been published ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results